Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate c...

Full description

Saved in:
Bibliographic Details
Published inEJNMMI research Vol. 10; no. 1; p. 46
Main Authors Yeh, Mei-Chun, Tse, Brian W. C., Fletcher, Nicholas L., Houston, Zachary H., Lund, Maria, Volpert, Marianna, Stewart, Chelsea, Sokolowski, Kamil A., Jeet, Varinder, Thurecht, Kristofer J., Campbell, Douglas H., Walsh, Bradley J., Nelson, Colleen C., Russell, Pamela J.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 07.05.2020
Springer Nature B.V
SpringerOpen
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of 89 Zr-labelled Miltuximab® as an imaging agent, and 177 Lu-labelled Miltuximab® as a targeted beta therapy, in a mouse xenograft model of human prostate cancer. Methods Male BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [ 89 Zr]Zr-DFO-Miltuximab® followed by PET-CT imaging, or (b) 6 MBq [ 177 Lu]Lu-DOTA-Miltuximab® by Cerenkov imaging, and ex vivo assessment of biodistribution. In an initial tumour efficacy study, mice bearing DU-145 tumours were administered intravenously with 6 MBq [ 177 Lu]Lu-DOTA-Miltuximab® or control DOTA-Miltuximab® then euthanised after 27 days. In a subsequent survival efficacy study, tumour-bearing mice were given 3 or 10 MBq of [ 177 Lu]Lu-DOTA-Miltuximab®, or control, and followed up to 120 days. Results Antibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [ 89 Zr]Zr-DFO-Miltuximab® and confirmed by Cerenkov luminescence imaging post injection of [ 177 Lu]Lu-DOTA-Miltuximab®. Antibody accumulation was higher (% IA/g) in tumours than other organs across multiple time points. A single injection with 6 MBq of [ 177 Lu]Lu-DOTA-Miltuximab® significantly inhibited tumour growth as compared with DOTA-Miltuximab® (control). In the survival study, mice treated with 10 MBq [ 177 Lu]Lu-DOTA-Miltuximab® had significantly prolonged survival (mean 85 days) versus control (45 days), an effect associated with increased cancer cell apoptosis. Tissue histopathology assessment showed no abnormalities associated with [ 177 Lu]Lu-DOTA-Miltuximab®, in line with other observations of tolerability, including body weight stability. Conclusion These findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([ 89 Zr]Zr-DFO-Miltuximab®) and a beta therapy ([ 177 Lu]Lu-DOTA-Miltuximab®) in patients with PCa or other GPC-1 expressing tumours.
AbstractList Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of 89Zr-labelled Miltuximab® as an imaging agent, and 177Lu-labelled Miltuximab® as a targeted beta therapy, in a mouse xenograft model of human prostate cancer. Methods Male BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [89Zr]Zr-DFO-Miltuximab® followed by PET-CT imaging, or (b) 6 MBq [177Lu]Lu-DOTA-Miltuximab® by Cerenkov imaging, and ex vivo assessment of biodistribution. In an initial tumour efficacy study, mice bearing DU-145 tumours were administered intravenously with 6 MBq [177Lu]Lu-DOTA-Miltuximab® or control DOTA-Miltuximab® then euthanised after 27 days. In a subsequent survival efficacy study, tumour-bearing mice were given 3 or 10 MBq of [177Lu]Lu-DOTA-Miltuximab®, or control, and followed up to 120 days. Results Antibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [89Zr]Zr-DFO-Miltuximab® and confirmed by Cerenkov luminescence imaging post injection of [177Lu]Lu-DOTA-Miltuximab®. Antibody accumulation was higher (% IA/g) in tumours than other organs across multiple time points. A single injection with 6 MBq of [177Lu]Lu-DOTA-Miltuximab® significantly inhibited tumour growth as compared with DOTA-Miltuximab® (control). In the survival study, mice treated with 10 MBq [177Lu]Lu-DOTA-Miltuximab® had significantly prolonged survival (mean 85 days) versus control (45 days), an effect associated with increased cancer cell apoptosis. Tissue histopathology assessment showed no abnormalities associated with [177Lu]Lu-DOTA-Miltuximab®, in line with other observations of tolerability, including body weight stability. Conclusion These findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([89Zr]Zr-DFO-Miltuximab®) and a beta therapy ([177Lu]Lu-DOTA-Miltuximab®) in patients with PCa or other GPC-1 expressing tumours.
PURPOSEChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of 89Zr-labelled Miltuximab® as an imaging agent, and 177Lu-labelled Miltuximab® as a targeted beta therapy, in a mouse xenograft model of human prostate cancer. METHODSMale BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [89Zr]Zr-DFO-Miltuximab® followed by PET-CT imaging, or (b) 6 MBq [177Lu]Lu-DOTA-Miltuximab® by Cerenkov imaging, and ex vivo assessment of biodistribution. In an initial tumour efficacy study, mice bearing DU-145 tumours were administered intravenously with 6 MBq [177Lu]Lu-DOTA-Miltuximab® or control DOTA-Miltuximab® then euthanised after 27 days. In a subsequent survival efficacy study, tumour-bearing mice were given 3 or 10 MBq of [177Lu]Lu-DOTA-Miltuximab®, or control, and followed up to 120 days. RESULTSAntibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [89Zr]Zr-DFO-Miltuximab® and confirmed by Cerenkov luminescence imaging post injection of [177Lu]Lu-DOTA-Miltuximab®. Antibody accumulation was higher (% IA/g) in tumours than other organs across multiple time points. A single injection with 6 MBq of [177Lu]Lu-DOTA-Miltuximab® significantly inhibited tumour growth as compared with DOTA-Miltuximab® (control). In the survival study, mice treated with 10 MBq [177Lu]Lu-DOTA-Miltuximab® had significantly prolonged survival (mean 85 days) versus control (45 days), an effect associated with increased cancer cell apoptosis. Tissue histopathology assessment showed no abnormalities associated with [177Lu]Lu-DOTA-Miltuximab®, in line with other observations of tolerability, including body weight stability. CONCLUSIONThese findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([89Zr]Zr-DFO-Miltuximab®) and a beta therapy ([177Lu]Lu-DOTA-Miltuximab®) in patients with PCa or other GPC-1 expressing tumours.
Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of 89 Zr-labelled Miltuximab® as an imaging agent, and 177 Lu-labelled Miltuximab® as a targeted beta therapy, in a mouse xenograft model of human prostate cancer. Methods Male BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [ 89 Zr]Zr-DFO-Miltuximab® followed by PET-CT imaging, or (b) 6 MBq [ 177 Lu]Lu-DOTA-Miltuximab® by Cerenkov imaging, and ex vivo assessment of biodistribution. In an initial tumour efficacy study, mice bearing DU-145 tumours were administered intravenously with 6 MBq [ 177 Lu]Lu-DOTA-Miltuximab® or control DOTA-Miltuximab® then euthanised after 27 days. In a subsequent survival efficacy study, tumour-bearing mice were given 3 or 10 MBq of [ 177 Lu]Lu-DOTA-Miltuximab®, or control, and followed up to 120 days. Results Antibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [ 89 Zr]Zr-DFO-Miltuximab® and confirmed by Cerenkov luminescence imaging post injection of [ 177 Lu]Lu-DOTA-Miltuximab®. Antibody accumulation was higher (% IA/g) in tumours than other organs across multiple time points. A single injection with 6 MBq of [ 177 Lu]Lu-DOTA-Miltuximab® significantly inhibited tumour growth as compared with DOTA-Miltuximab® (control). In the survival study, mice treated with 10 MBq [ 177 Lu]Lu-DOTA-Miltuximab® had significantly prolonged survival (mean 85 days) versus control (45 days), an effect associated with increased cancer cell apoptosis. Tissue histopathology assessment showed no abnormalities associated with [ 177 Lu]Lu-DOTA-Miltuximab®, in line with other observations of tolerability, including body weight stability. Conclusion These findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([ 89 Zr]Zr-DFO-Miltuximab®) and a beta therapy ([ 177 Lu]Lu-DOTA-Miltuximab®) in patients with PCa or other GPC-1 expressing tumours.
ArticleNumber 46
Author Walsh, Bradley J.
Sokolowski, Kamil A.
Lund, Maria
Stewart, Chelsea
Russell, Pamela J.
Fletcher, Nicholas L.
Volpert, Marianna
Houston, Zachary H.
Jeet, Varinder
Yeh, Mei-Chun
Thurecht, Kristofer J.
Campbell, Douglas H.
Tse, Brian W. C.
Nelson, Colleen C.
Author_xml – sequence: 1
  givenname: Mei-Chun
  surname: Yeh
  fullname: Yeh, Mei-Chun
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
– sequence: 2
  givenname: Brian W. C.
  surname: Tse
  fullname: Tse, Brian W. C.
  organization: Preclinical Imaging Facility, Translational Research Institute
– sequence: 3
  givenname: Nicholas L.
  surname: Fletcher
  fullname: Fletcher, Nicholas L.
  organization: Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland
– sequence: 4
  givenname: Zachary H.
  surname: Houston
  fullname: Houston, Zachary H.
  organization: Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland
– sequence: 5
  givenname: Maria
  surname: Lund
  fullname: Lund, Maria
  organization: Glytherix Ltd
– sequence: 6
  givenname: Marianna
  surname: Volpert
  fullname: Volpert, Marianna
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
– sequence: 7
  givenname: Chelsea
  surname: Stewart
  fullname: Stewart, Chelsea
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
– sequence: 8
  givenname: Kamil A.
  surname: Sokolowski
  fullname: Sokolowski, Kamil A.
  organization: Preclinical Imaging Facility, Translational Research Institute
– sequence: 9
  givenname: Varinder
  surname: Jeet
  fullname: Jeet, Varinder
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
– sequence: 10
  givenname: Kristofer J.
  surname: Thurecht
  fullname: Thurecht, Kristofer J.
  organization: Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland
– sequence: 11
  givenname: Douglas H.
  surname: Campbell
  fullname: Campbell, Douglas H.
  organization: Glytherix Ltd
– sequence: 12
  givenname: Bradley J.
  surname: Walsh
  fullname: Walsh, Bradley J.
  organization: Glytherix Ltd
– sequence: 13
  givenname: Colleen C.
  surname: Nelson
  fullname: Nelson, Colleen C.
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
– sequence: 14
  givenname: Pamela J.
  surname: Russell
  fullname: Russell, Pamela J.
  email: pamela.russell@qut.edu.au
  organization: Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute
BookMark eNp9kstu1DAUhiNURC_0BVhZYlMWAd_ixBskNIJSaRAsisTOOrFPMhll4sF2ysxL8RA8Wd1OBZQFlnyR_f-fjnz-0-Jo8hMWxQtGXzPWqDeRiaqiJeV5UiXqcvekOOFMszIv347-Oh8X5zGuaR4Vq7RonhXHgouGa05Pis01hB4TOtJiApJWGGC7J74j2-BjgoTEwmQxkB9DWhFW18u5HKHFccyeT8OY5t2wgfbXTwJTGlrv9gR6GKaYSD_ut0N2l4xcXH5ZlOzV8-JpB2PE84f9rPj64f314mO5_Hx5tXi3LK2UdSp1JxmTmit0yrqGcyGYbpmtgaOtqVCUCQYcQELDJaB1qJRrdes007WsxFlxdeA6D2uzDbnCsDceBnN_4UNvIKTBjmg4dtw2KFyjlHQ1NIrV2FWU0RYE1V1mvT2wtnO7QWdxSgHGR9DHL9OwMr2_MTWnSjY0Ay4eAMF_nzEmsxmizR8IE_o5Gi5zZ2Ru4Z305T_StZ_DlL_KcKG1EpwzllX8oLK5RTFg97sYRs1dOMwhHCaHw9yHw-yySRxMMYunHsMf9H9ctzCLvSY
CitedBy_id crossref_primary_10_1021_acs_molpharmaceut_2c00760
crossref_primary_10_1007_s10967_021_08174_0
crossref_primary_10_1016_j_drudis_2023_103660
crossref_primary_10_18632_oncotarget_28388
crossref_primary_10_1016_j_cclet_2022_03_056
crossref_primary_10_1152_ajpcell_00290_2021
crossref_primary_10_1007_s10967_021_07979_3
crossref_primary_10_1021_acs_jmedchem_3c00472
crossref_primary_10_1016_j_radphyschem_2024_111687
crossref_primary_10_1177_17588359211022918
crossref_primary_10_1038_s41598_024_66838_9
crossref_primary_10_1080_14712598_2022_2033204
crossref_primary_10_1016_j_pdpdt_2020_102064
Cites_doi 10.1038/modpathol.2017.190
10.1016/j.clgc.2016.08.018
10.1002/ijc.2910500616
10.1002/cam4.1064
10.1002/ijc.31124
10.1007/BF02789226
10.1038/s41598-017-14218-x
10.1038/nrclinonc.2014.72
10.1002/jmrs.227
10.7150/jca.14645
10.1016/j.jim.2017.03.013
10.1007/s00259-017-3751-z
10.1158/1078-0432.CCR-08-1203
10.1038/nrm1681
10.1016/j.wneu.2017.05.165
10.1200/JCO.2017.35.6_suppl.e565
10.1186/1749-8104-4-33
10.1038/s41379-018-0066-y
10.1016/j.pacs.2018.05.001
10.1007/BF03033865
10.1038/bjc.2016.183
10.1016/S1470-2045(18)30198-0
10.1111/j.1464-410X.2005.05798.x
10.3389/fphar.2016.00131
10.1016/S0022-5347(17)39172-3
10.1002/ijc.2910210305
10.1158/1078-0432.CCR-13-0231
10.3322/caac.21590
10.1136/bmj.39498.525706.AD
10.3389/fonc.2019.00614
10.1039/C4PY00999A
10.1002/cncr.32072
10.18632/oncotarget.15799
10.18632/oncotarget.25009
10.1177/1536012118776068
ContentType Journal Article
Copyright The Author(s) 2020
The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
8AO
8FE
8FG
8FI
8FJ
8FK
ABUWG
AFKRA
ARAPS
AZQEC
BENPR
BGLVJ
CCPQU
DWQXO
FYUFA
GHDGH
HCIFZ
K9.
M0S
P5Z
P62
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13550-020-00637-x
DatabaseName SpringerOpen
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
ProQuest Central
Technology Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Technology Collection
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Advanced Technologies & Aerospace Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Advanced Technologies & Aerospace Database
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2191-219X
EndPage 46
ExternalDocumentID oai_doaj_org_article_2ef2c8e3d8664d7a8617ef5010ba309f
10_1186_s13550_020_00637_x
GrantInformation_xml – fundername: National Health and Medical Research Council
  grantid: APP1093539
  funderid: http://dx.doi.org/10.13039/501100000925
– fundername: ;
  grantid: APP1093539
GroupedDBID -A0
0R~
3V.
40G
53G
5VS
7X7
8AO
8FE
8FG
8FI
8FJ
AAFWJ
AAJSJ
AAKKN
AAPBV
AAYZJ
ABDBF
ABUWG
ACACY
ACGFS
ACIHN
ADBBV
ADINQ
AEAQA
AENEX
AFGXO
AFKRA
AFNRJ
AFPKN
AHBXF
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ARAPS
BAPOH
BCNDV
BENPR
BFQNJ
BGLVJ
BPHCQ
BVXVI
C24
C6C
CCPQU
EBS
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
KQ8
M48
M~E
OK1
P62
PIMPY
PQQKQ
PROAC
RBZ
RNS
RPM
RSV
SMD
SOJ
U2A
UKHRP
AAYXX
ABEEZ
ACULB
ALIPV
CITATION
EBLON
ITC
PGMZT
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c447t-9f4114926ed6cd8223319b1c7a2ec70360131a2aa4a824aecde66db9bd9197453
IEDL.DBID RPM
ISSN 2191-219X
IngestDate Tue Oct 22 15:16:00 EDT 2024
Tue Sep 17 21:03:52 EDT 2024
Sat Oct 05 05:47:29 EDT 2024
Thu Oct 10 16:52:31 EDT 2024
Thu Nov 21 23:57:24 EST 2024
Sat Dec 16 12:03:45 EST 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Miltuximab
Radionuclide therapy
Glypican-1
Prostate cancer
MIL-38
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c447t-9f4114926ed6cd8223319b1c7a2ec70360131a2aa4a824aecde66db9bd9197453
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206480/
PMID 32382920
PQID 2399632211
PQPubID 2034773
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_2ef2c8e3d8664d7a8617ef5010ba309f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7206480
proquest_miscellaneous_2400546370
proquest_journals_2399632211
crossref_primary_10_1186_s13550_020_00637_x
springer_journals_10_1186_s13550_020_00637_x
PublicationCentury 2000
PublicationDate 2020-05-07
PublicationDateYYYYMMDD 2020-05-07
PublicationDate_xml – month: 05
  year: 2020
  text: 2020-05-07
  day: 07
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Heidelberg
PublicationTitle EJNMMI research
PublicationTitleAbbrev EJNMMI Res
PublicationYear 2020
Publisher Springer Berlin Heidelberg
Springer Nature B.V
SpringerOpen
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
– name: SpringerOpen
References Sharifi, Dahut, Steinberg, Figg, Tarassoff, Arlen (CR4) 2005; 96
Russell, Ow, Tam, Juarez, Kingsley, Qu (CR7) 2004; 53
Li, Song, Rizvi, Power, Beretov, Raja (CR15) 2009; 15
Bräuer, Grubert, Roll, Schrader, Schäfers, Bögemann (CR32) 2017; 44
Lightfoot, Walker, Boniface, Hetherington, Izard, Russell (CR12) 1991; 4
Lu, Niu, Liu, Gao, Sun, Zhao (CR34) 2017; 6
CR19
Moreira, Howard, Sourbeer, Amarasekara, Chow, Cockrell (CR5) 2017; 15
Boyle, Paine, Mather (CR22) 1992; 50
Saito, Sugiyama, Hama, Yamasaki, Takayasu, Nosaka (CR36) 2017; 105
Corwin, Ebrahimi-Nik, Floyd, Tavousi, Mandoiu, Srivastava (CR20) 2017; 445
Russell, Davis, Kingsley, Humphreys, Hanley, O’Grady (CR13) 1994; 24–25
CR11
Lee, Kim, Lee, Zen, Han (CR24) 2017; 7
CR10
Truong, Justiniano, Nocon, Soon, Wissmueller, Campbell (CR8) 2016; 7
Li, Tang, Yao (CR25) 2018; 10
Matsuda, Maruyama, Guo, Kleeff, Itakura, Matsumoto (CR35) 2001; 61
Harada, Serada, Fujimoto, Takahashi, Takahashi, Hara (CR27) 2017; 8
Tagawa, Milowsky, Morris, Vallabhajosula, Christos, Akhtar (CR18) 2013; 19
Matsuzaki, Serada, Hiramatsu, Nojima, Matsuzaki, Ueda (CR26) 2018; 142
Hara, Takahashi, Serada, Fujimoto, Ohkawara, Nakatsuka (CR37) 2016; 115
Chiu, Lee, Cheung, Churg (CR39) 2018; 31
Emmett, Willowson, Violet, Shin, Blanksby, Lee (CR30) 2017; 64
Häcker, Nybakken, Perrimon (CR9) 2005; 6
Russell, Plomley, Shon, O’Grady, Pearce (CR14) 1993; 22
Gurney, Sabanathan, Gillatt, Poursoultan, Ho Shon, Walsh (CR16) 2017; 35
Koizumi, Endo, Watanabe, Saga, Sakahara, Konishi (CR23) 1989; 49
Siegel, Miller, Jemal (CR1) 2020; 70
Wong, Ferraldeschi, Attard, De Bono (CR3) 2014; 11
Tagawa, Vallabhajosula, Christos, Jhanwar, Batra, Lam (CR33) 2019; 125
Jauw, Menke-van der Houven van Oordt, Hoekstra, Hendrikse, Vugts, Zijlstra (CR17) 2016; 7
Jen, Musacchio, Lander (CR28) 2009; 4
Levin, Lund, Truong, Wu, Shore, Saltzstein (CR29) 2018; 9
Hofman, Violet, Hicks, Ferdinandus, Ping Thang, Akhurst (CR31) 2018; 6
Walker, Russell, Kingsley, Philips, Raghavan (CR6) 1989; 142
Graham, Baker, Macbeth, Titshall (CR2) 2008; 336
Stone, Mickey, Wunderli, Mickey, Paulson (CR21) 1978; 21
Amatya, Kushitani, Kai, Suzuki, Miyata, Okada (CR38) 2018; 31
637_CR10
PJ Russell (637_CR13) 1994; 24–25
PJ Russell (637_CR7) 2004; 53
637_CR11
M Li (637_CR25) 2018; 10
RL Siegel (637_CR1) 2020; 70
Y Li (637_CR15) 2009; 15
S Matsuzaki (637_CR26) 2018; 142
E Harada (637_CR27) 2017; 8
MS Hofman (637_CR31) 2018; 6
T Saito (637_CR36) 2017; 105
ST Tagawa (637_CR33) 2019; 125
J Graham (637_CR2) 2008; 336
CC Boyle (637_CR22) 1992; 50
637_CR19
YWS Jauw (637_CR17) 2016; 7
H Gurney (637_CR16) 2017; 35
YHL Jen (637_CR28) 2009; 4
KZ Walker (637_CR6) 1989; 142
KR Stone (637_CR21) 1978; 21
ST Tagawa (637_CR18) 2013; 19
K Matsuda (637_CR35) 2001; 61
H Hara (637_CR37) 2016; 115
YNS Wong (637_CR3) 2014; 11
PJ Russell (637_CR14) 1993; 22
RA Levin (637_CR29) 2018; 9
S Lee (637_CR24) 2017; 7
DV Lightfoot (637_CR12) 1991; 4
K Chiu (637_CR39) 2018; 31
Q Truong (637_CR8) 2016; 7
WL Corwin (637_CR20) 2017; 445
H Lu (637_CR34) 2017; 6
DM Moreira (637_CR5) 2017; 15
M Koizumi (637_CR23) 1989; 49
A Bräuer (637_CR32) 2017; 44
N Sharifi (637_CR4) 2005; 96
L Emmett (637_CR30) 2017; 64
U Häcker (637_CR9) 2005; 6
VJ Amatya (637_CR38) 2018; 31
References_xml – volume: 31
  start-page: 809
  year: 2018
  end-page: 815
  ident: CR38
  article-title: Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
  publication-title: Mod Pathol.
  doi: 10.1038/modpathol.2017.190
  contributor:
    fullname: Okada
– volume: 15
  start-page: 60
  year: 2017
  end-page: 66e2
  ident: CR5
  article-title: Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH
  publication-title: Clin Genitourin Cancer.
  doi: 10.1016/j.clgc.2016.08.018
  contributor:
    fullname: Cockrell
– volume: 50
  start-page: 1443
  year: 1992
  end-page: 1452
  ident: CR22
  article-title: The mechanism of hepatic uptake of a radiolabelled monoclonal antibody
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.2910500616
  contributor:
    fullname: Mather
– volume: 6
  start-page: 1181
  year: 2017
  end-page: 1191
  ident: CR34
  article-title: Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1064
  contributor:
    fullname: Zhao
– volume: 142
  start-page: 1056
  year: 2018
  end-page: 1066
  ident: CR26
  article-title: Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.31124
  contributor:
    fullname: Ueda
– volume: 24–25
  start-page: 155
  year: 1994
  end-page: 161
  ident: CR13
  article-title: Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer
  publication-title: Cell Biophys.
  doi: 10.1007/BF02789226
  contributor:
    fullname: O’Grady
– ident: CR10
– volume: 49
  start-page: 1752
  year: 1989
  end-page: 1757
  ident: CR23
  article-title: Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice
  publication-title: Cancer Res.
  contributor:
    fullname: Konishi
– volume: 7
  start-page: 14203
  year: 2017
  ident: CR24
  article-title: Imaging monitoring of Kupffer cell function and hepatic oxygen saturation in preneoplastic changes during cholangiocarcinogenesis
  publication-title: Sci Rep.
  doi: 10.1038/s41598-017-14218-x
  contributor:
    fullname: Han
– volume: 11
  start-page: 365
  year: 2014
  end-page: 376
  ident: CR3
  article-title: Evolution of androgen receptor targeted therapy for advanced prostate cancer
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2014.72
  contributor:
    fullname: De Bono
– volume: 8
  start-page: 24741
  year: 2017
  end-page: 24752
  ident: CR27
  article-title: Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
  publication-title: Oncotarget.
  contributor:
    fullname: Hara
– volume: 64
  start-page: 52
  year: 2017
  end-page: 60
  ident: CR30
  article-title: Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
  publication-title: J Med Radiat Sci.
  doi: 10.1002/jmrs.227
  contributor:
    fullname: Lee
– volume: 7
  start-page: 1002
  year: 2016
  end-page: 1009
  ident: CR8
  article-title: Glypican-1 as a biomarker for prostate cancer: isolation and characterization
  publication-title: J Cancer.
  doi: 10.7150/jca.14645
  contributor:
    fullname: Campbell
– volume: 445
  start-page: 71
  year: 2017
  end-page: 76
  ident: CR20
  article-title: Tumor Control Index as a new tool to assess tumor growth in experimental animals
  publication-title: J Immunol Methods.
  doi: 10.1016/j.jim.2017.03.013
  contributor:
    fullname: Srivastava
– volume: 9
  start-page: 22359
  year: 2018
  end-page: 22367
  ident: CR29
  article-title: Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker
  publication-title: Oncotarget.
  contributor:
    fullname: Saltzstein
– volume: 44
  start-page: 1663
  year: 2017
  end-page: 1670
  ident: CR32
  article-title: 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
  publication-title: Eur J Nucl Med Mol Imaging.
  doi: 10.1007/s00259-017-3751-z
  contributor:
    fullname: Bögemann
– volume: 125
  start-page: 2561
  year: 2019
  end-page: 2569
  ident: CR33
  article-title: Phase 1/2 study of fractionated dose lutetium-177–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer
  publication-title: Cancer.
  contributor:
    fullname: Lam
– volume: 15
  start-page: 865
  year: 2009
  end-page: 875
  ident: CR15
  article-title: Inhibition of micrometastatic prostate cancer cell spread in animal models by213bilabeled multipletargeted α radioimmunoconjugates
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-1203
  contributor:
    fullname: Raja
– volume: 6
  start-page: 530
  year: 2005
  end-page: 541
  ident: CR9
  article-title: Heparan sulphate proteoglycans: the sweet side of development
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1681
  contributor:
    fullname: Perrimon
– volume: 105
  start-page: 282
  year: 2017
  end-page: 288
  ident: CR36
  article-title: High expression of glypican-1 predicts dissemination and poor prognosis in glioblastomas
  publication-title: World Neurosurg.
  doi: 10.1016/j.wneu.2017.05.165
  contributor:
    fullname: Nosaka
– ident: CR19
– volume: 35
  start-page: e565
  year: 2017
  ident: CR16
  article-title: MILGa-01: a first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.35.6_suppl.e565
  contributor:
    fullname: Walsh
– volume: 53
  start-page: 995
  year: 2004
  end-page: 1004
  ident: CR7
  article-title: Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer
  publication-title: Cancer Immunol Immunother.
  contributor:
    fullname: Qu
– volume: 61
  start-page: 5562
  year: 2001
  end-page: 5569
  ident: CR35
  article-title: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells
  publication-title: Cancer Res.
  contributor:
    fullname: Matsumoto
– volume: 4
  start-page: 1
  year: 2009
  end-page: 19
  ident: CR28
  article-title: Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis
  publication-title: Neural Dev.
  doi: 10.1186/1749-8104-4-33
  contributor:
    fullname: Lander
– volume: 31
  start-page: 1400
  year: 2018
  end-page: 1403
  ident: CR39
  article-title: Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma
  publication-title: Mod Pathol.
  doi: 10.1038/s41379-018-0066-y
  contributor:
    fullname: Churg
– volume: 10
  start-page: 65
  year: 2018
  end-page: 73
  ident: CR25
  article-title: Photoacoustic tomography of blood oxygenation: a mini review
  publication-title: Photoacoustics.
  doi: 10.1016/j.pacs.2018.05.001
  contributor:
    fullname: Yao
– volume: 22
  start-page: 27
  year: 1993
  end-page: 47
  ident: CR14
  article-title: Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer
  publication-title: Cell Biophys.
  doi: 10.1007/BF03033865
  contributor:
    fullname: Pearce
– volume: 115
  start-page: 66
  year: 2016
  end-page: 75
  ident: CR37
  article-title: Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
  publication-title: Br J Cancer.
  doi: 10.1038/bjc.2016.183
  contributor:
    fullname: Nakatsuka
– volume: 6
  start-page: 825
  year: 2018
  end-page: 833
  ident: CR31
  article-title: [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30198-0
  contributor:
    fullname: Akhurst
– ident: CR11
– volume: 96
  start-page: 985
  year: 2005
  end-page: 989
  ident: CR4
  article-title: A retrospective study of the time to clinical endpoints for advanced prostate cancer
  publication-title: BJU Int.
  doi: 10.1111/j.1464-410X.2005.05798.x
  contributor:
    fullname: Arlen
– volume: 4
  start-page: 319
  year: 1991
  end-page: 330
  ident: CR12
  article-title: Dosimetric and therapeutic studies in nude mice xenograft models with 153Samarium-labelled monoclonal antibody, BLCA-38
  publication-title: Antib Immunoconjugates Radiopharm.
  contributor:
    fullname: Russell
– volume: 7
  start-page: 131
  year: 2016
  ident: CR17
  article-title: Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2016.00131
  contributor:
    fullname: Zijlstra
– volume: 142
  start-page: 1578
  year: 1989
  end-page: 1583
  ident: CR6
  article-title: Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay
  publication-title: J Urol.
  doi: 10.1016/S0022-5347(17)39172-3
  contributor:
    fullname: Raghavan
– volume: 21
  start-page: 274
  year: 1978
  end-page: 281
  ident: CR21
  article-title: Isolation of a human prostate carcinoma cell line (DU 145)
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.2910210305
  contributor:
    fullname: Paulson
– volume: 19
  start-page: 5182
  year: 2013
  end-page: 5191
  ident: CR18
  article-title: Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-0231
  contributor:
    fullname: Akhtar
– volume: 70
  start-page: 7
  year: 2020
  end-page: 30
  ident: CR1
  article-title: Cancer statistics, 2020
  publication-title: CA Cancer J Clin.
  doi: 10.3322/caac.21590
  contributor:
    fullname: Jemal
– volume: 336
  start-page: 610
  year: 2008
  end-page: 612
  ident: CR2
  article-title: Diagnosis and treatment of prostate cancer: Summary of NICE guidance
  publication-title: BMJ.
  doi: 10.1136/bmj.39498.525706.AD
  contributor:
    fullname: Titshall
– volume: 336
  start-page: 610
  year: 2008
  ident: 637_CR2
  publication-title: BMJ.
  doi: 10.1136/bmj.39498.525706.AD
  contributor:
    fullname: J Graham
– volume: 7
  start-page: 14203
  year: 2017
  ident: 637_CR24
  publication-title: Sci Rep.
  doi: 10.1038/s41598-017-14218-x
  contributor:
    fullname: S Lee
– ident: 637_CR10
  doi: 10.3389/fonc.2019.00614
– volume: 142
  start-page: 1578
  year: 1989
  ident: 637_CR6
  publication-title: J Urol.
  doi: 10.1016/S0022-5347(17)39172-3
  contributor:
    fullname: KZ Walker
– volume: 61
  start-page: 5562
  year: 2001
  ident: 637_CR35
  publication-title: Cancer Res.
  contributor:
    fullname: K Matsuda
– volume: 31
  start-page: 1400
  year: 2018
  ident: 637_CR39
  publication-title: Mod Pathol.
  doi: 10.1038/s41379-018-0066-y
  contributor:
    fullname: K Chiu
– volume: 115
  start-page: 66
  year: 2016
  ident: 637_CR37
  publication-title: Br J Cancer.
  doi: 10.1038/bjc.2016.183
  contributor:
    fullname: H Hara
– volume: 70
  start-page: 7
  year: 2020
  ident: 637_CR1
  publication-title: CA Cancer J Clin.
  doi: 10.3322/caac.21590
  contributor:
    fullname: RL Siegel
– volume: 4
  start-page: 1
  year: 2009
  ident: 637_CR28
  publication-title: Neural Dev.
  doi: 10.1186/1749-8104-4-33
  contributor:
    fullname: YHL Jen
– volume: 19
  start-page: 5182
  year: 2013
  ident: 637_CR18
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-0231
  contributor:
    fullname: ST Tagawa
– ident: 637_CR19
  doi: 10.1039/C4PY00999A
– volume: 4
  start-page: 319
  year: 1991
  ident: 637_CR12
  publication-title: Antib Immunoconjugates Radiopharm.
  contributor:
    fullname: DV Lightfoot
– volume: 49
  start-page: 1752
  year: 1989
  ident: 637_CR23
  publication-title: Cancer Res.
  contributor:
    fullname: M Koizumi
– volume: 15
  start-page: 865
  year: 2009
  ident: 637_CR15
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-1203
  contributor:
    fullname: Y Li
– volume: 35
  start-page: e565
  year: 2017
  ident: 637_CR16
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.35.6_suppl.e565
  contributor:
    fullname: H Gurney
– volume: 6
  start-page: 825
  year: 2018
  ident: 637_CR31
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30198-0
  contributor:
    fullname: MS Hofman
– volume: 31
  start-page: 809
  year: 2018
  ident: 637_CR38
  publication-title: Mod Pathol.
  doi: 10.1038/modpathol.2017.190
  contributor:
    fullname: VJ Amatya
– volume: 96
  start-page: 985
  year: 2005
  ident: 637_CR4
  publication-title: BJU Int.
  doi: 10.1111/j.1464-410X.2005.05798.x
  contributor:
    fullname: N Sharifi
– volume: 125
  start-page: 2561
  year: 2019
  ident: 637_CR33
  publication-title: Cancer.
  doi: 10.1002/cncr.32072
  contributor:
    fullname: ST Tagawa
– volume: 6
  start-page: 530
  year: 2005
  ident: 637_CR9
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1681
  contributor:
    fullname: U Häcker
– volume: 7
  start-page: 131
  year: 2016
  ident: 637_CR17
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2016.00131
  contributor:
    fullname: YWS Jauw
– volume: 22
  start-page: 27
  year: 1993
  ident: 637_CR14
  publication-title: Cell Biophys.
  doi: 10.1007/BF03033865
  contributor:
    fullname: PJ Russell
– volume: 6
  start-page: 1181
  year: 2017
  ident: 637_CR34
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1064
  contributor:
    fullname: H Lu
– volume: 15
  start-page: 60
  year: 2017
  ident: 637_CR5
  publication-title: Clin Genitourin Cancer.
  doi: 10.1016/j.clgc.2016.08.018
  contributor:
    fullname: DM Moreira
– volume: 10
  start-page: 65
  year: 2018
  ident: 637_CR25
  publication-title: Photoacoustics.
  doi: 10.1016/j.pacs.2018.05.001
  contributor:
    fullname: M Li
– volume: 53
  start-page: 995
  year: 2004
  ident: 637_CR7
  publication-title: Cancer Immunol Immunother.
  contributor:
    fullname: PJ Russell
– volume: 7
  start-page: 1002
  year: 2016
  ident: 637_CR8
  publication-title: J Cancer.
  doi: 10.7150/jca.14645
  contributor:
    fullname: Q Truong
– volume: 105
  start-page: 282
  year: 2017
  ident: 637_CR36
  publication-title: World Neurosurg.
  doi: 10.1016/j.wneu.2017.05.165
  contributor:
    fullname: T Saito
– volume: 50
  start-page: 1443
  year: 1992
  ident: 637_CR22
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.2910500616
  contributor:
    fullname: CC Boyle
– volume: 24–25
  start-page: 155
  year: 1994
  ident: 637_CR13
  publication-title: Cell Biophys.
  doi: 10.1007/BF02789226
  contributor:
    fullname: PJ Russell
– volume: 142
  start-page: 1056
  year: 2018
  ident: 637_CR26
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.31124
  contributor:
    fullname: S Matsuzaki
– volume: 11
  start-page: 365
  year: 2014
  ident: 637_CR3
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2014.72
  contributor:
    fullname: YNS Wong
– volume: 8
  start-page: 24741
  year: 2017
  ident: 637_CR27
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.15799
  contributor:
    fullname: E Harada
– volume: 9
  start-page: 22359
  year: 2018
  ident: 637_CR29
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.25009
  contributor:
    fullname: RA Levin
– volume: 64
  start-page: 52
  year: 2017
  ident: 637_CR30
  publication-title: J Med Radiat Sci.
  doi: 10.1002/jmrs.227
  contributor:
    fullname: L Emmett
– volume: 445
  start-page: 71
  year: 2017
  ident: 637_CR20
  publication-title: J Immunol Methods.
  doi: 10.1016/j.jim.2017.03.013
  contributor:
    fullname: WL Corwin
– ident: 637_CR11
  doi: 10.1177/1536012118776068
– volume: 21
  start-page: 274
  year: 1978
  ident: 637_CR21
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.2910210305
  contributor:
    fullname: KR Stone
– volume: 44
  start-page: 1663
  year: 2017
  ident: 637_CR32
  publication-title: Eur J Nucl Med Mol Imaging.
  doi: 10.1007/s00259-017-3751-z
  contributor:
    fullname: A Bräuer
SSID ssj0000515938
Score 2.295514
Snippet Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy....
PurposeChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab®...
PURPOSEChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab®...
Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy....
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Publisher
StartPage 46
SubjectTerms Abnormalities
Accumulation
Antibodies
Apoptosis
Bearing
Body weight
Cardiac Imaging
Computed tomography
Glypican-1
Imaging
Lutetium isotopes
Medical imaging
Medicine
Medicine & Public Health
MIL-38
Miltuximab
Novel Theragnostic Drugs
Nuclear Medicine
Oncology
Organs
Original Research
Orthopedics
Positron emission
Prostate cancer
Radiology
Radionuclide therapy
Survival
Therapy
Tomography
Tumors
Xenotransplantation
Zirconium isotopes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxUxFA7ShbgR6wPHVongQtHQSSaTx7IWaxGvuGihu5DX1IF27qWdC_f-qf4If1lPMnNrpyBu3E4yJDnP7yQ5Jwi9C0IrWntHeKxLwhn3BEIwiFqlryLX3jGfEpxnP8TRCf92Wp_eeeor3QkbygMPhNtjsWFexSooIXiQVoHLjU0NYYSzVambbH1LdieYGqt617pSmywZJfauKHjWkqRoKbllSVYTT5QL9k9Q5v07kvcOSrP_OXyCHo_AEe8PE95GD2L3FD2cjUfjz9DFcb7THQN2sbd4yKta43mDFymxAyAl9onDlzhtvWIq5fclARFIG_cBz9rzfrlqL6z7fY2B2K2bhzW2Z7YF-IjPzteLZC4Jxe-__jwg9MNzdHL45fjgiIxvKRDPueyJbjhEPpqJGIQPgAoq0D1HvbQs-lSEK9XdscxabhXjNvoQhQhOu6AphBx19QJtdfMuvkSYOdaUoWTaMsfBPqkmVgkFwgiVCJQV6OOGrmYxlMwwOdRQwgxcMMAFk7lgVgX6nEh_2zOVu84fQAjMKATmX0JQoN0N48yog1cmZe0KsFeUFujtbTNoTzoSsV2cL6EPT5gVJlIWSE4YPpnQtKVrf-U63JIBnlPw56eNaPwZ_O8LfvU_FryDHrEsyjVo1S7a6i-X8TWgo969yYpwA2AMCzk
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifuLqKRF8UDRck6ZJ-iR6uHeIKz7cwb2VfHUt3LXrbhd2_yn_CP8yZ7rtHj3Q16YlaebrNzOZCSFvgsoNz7xjMmYJk0J6Bi4YeK3ap1Hm3gmPBc6z7-r0XH69yC76gNuqP1Y56MROUYfGY4z8CGswFXAf5x8XvxjeGoXZ1f4KjdvkDhda4ZE-Mz3Zx1jw_pI8NUOtjFFHKw72NWHoM6Fx1mwzskdd2_4R1rx5UvJGurSzQtMH5H4PH-mnHb0fkluxfkTuzvoE-WNyddad7I6Buthauquu2tKmpAss7wBgST3SeUkxAEu51t_WDBgBw_eBzqrLdr2prqz785vClleuCVtq57YCEEnnl9sFKk3G6duTH8eMv3tCzqdfzo5PWX-jAvNS6pblpQT_JxcqBuUDYIMUJNBxr62IHltxYfcdK6yV1ghpow9RqeByF3IOjkeWPiUHdVPHZ4QKJ8okJCK3wknQUqaMKWJBmCFVgYsJeT_sa7HYNc4oOofDqGJHhQKoUHRUKDYT8hm3fv8mNr3uHjTLedHLUCFiKbyJaTBKyaCtAfQVyww8SmfTJC8n5HAgXNFL4qq45psJeb0fBhnCxIitY7OGdyQiV1hIMiF6RPDRgsYjdfWz68atBaA6A19-GFjjevJ___Dz_6_1BbknOibNQGoOyUG7XMeXgH5a96pj8b_q_wKW
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqIiEuiPIQgRYZiQMIDLHjOPEBIagoFWIRh660N8uvbCNtk2WblXb_FD-CX8bYmxSlKgcuOcRO4szD843tmUHohROypLk1hPs8JZxxS8AFA6-1sJnn0hpmQ4Dz5Ls4nfKvs3y2h4ZyRz0BL2907UI9qelq8Xbzc_sBFP59VPhSvLukYDRTEhyhYHELApjyFgPLGI54TXq43-f6zmUsbg16SglcZkMczY2vGdmqmNJ_hEOvn6K8tpUaLdTJPXS3h5b4404WDtCeb-6j25N-8_wBujiLp769w8Z3Gu8ir7a4rfAyhH4A6MQ2yMAKh8VZTIvi25qAkISlfYcn9aJbb-oLbX7_wsCO2rRui_Vc1wAw8XyxXYYJlVD88suPY0JfPUTTk89nx6ekr7ZALOdFR2TFwTeSTHgnrAPckIF2GmoLzbwNabpCZh7NtOa6ZFx767wQzkjjJAWnJM8eof2mbfxjhJlhVepSJjUzHGawsvJZwInwhUw4yhL0eqCrWu6SaqjojJRC7biggAsqckFtEvQpkP6qZ0iIHW-0q7nq9UsxXzFb-syVQnBX6BKQma9y8DaNzlJZJehwYJwahEyFuF4BMxqlCXp-1Qz6FTZNdOPbNfThAdXCQNIEFSOGjwY0bmnq85ipu2CA-Ep48s0gGn8__u8ffvJf5HmK7rAoszko2CHa71ZrfwRAqTPPovT_AQnKDAs
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Open Access Hybrid - NESLI2 2011-2012
  dbid: 40G
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQkRAXxFNsKchIHEBgETuO4xyhoq0Qizi0Um-WX1kitclqm5W6f4ofwS9jxptslQoOXGNbdjyemW88DxPyJqhK88I7JmORMSmkZ2CCgdVa-jzKyjvhMcF5_l2dnMmv58X5TR53CnYfPZJJUCeu1urjFQfNmDG0dlCtlgyA412M4cA4Ppkd7y5W8NGSKtdjgsxfh06UUKrVPwGYt8Mjb_lIk-o5ekgeDJiRftoS-RG5E9vH5N588Io_IZenKZw7Bupib-k2pWpDu5ouMacD0CT1SNwVxVtXysvy25oB9fHOPtB5c9Gvr5tL637_orDPjevChtqFbQA50sXFZomSknH69vjHIePvnpKzoy-nhydseEaBeSnLnlW1BKOnEioG5QMAghzYznFfWhE91t_CkjtWWCutFtJGH6JSwVUuVBysjSJ_Rvbaro3PCRVO1FnIRGWFkyCadB1zBIAwQ64CFzPyftxXs9xWyzDJytDKbKlggAomUcFcz8hn3PpdT6x0nT50q4UZGMeIWAuvYx60UjKUVgPkinUBZqSzeVbVM3IwEs4M7HdlMGFXgajifEZe75qBcdAbYtvYraGPRLgKC8lmpJwQfLKgaUvb_EwluEsBUE7DyA_j0biZ_N8_vP9_3V-Q-yId2gJY54Ds9at1fAkQqHev0pH_Ax6U_1g
  priority: 102
  providerName: Springer Nature
Title Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
URI https://link.springer.com/article/10.1186/s13550-020-00637-x
https://www.proquest.com/docview/2399632211
https://search.proquest.com/docview/2400546370
https://pubmed.ncbi.nlm.nih.gov/PMC7206480
https://doaj.org/article/2ef2c8e3d8664d7a8617ef5010ba309f
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2MvY5_MWxc02MPGpsaWZUl-bELTMpYSSgNhL0ZfTg2JE9IEmn9qf8T-sp0Uu1sKe9nL4S-QrLvT_U66OyH00fJcJpnRhLksJowyQ8AFA69VmNSx3GhqfILz8JJfjNm3STY5QFmbCxOC9o2uTurZ_KSubkJs5XJuum2cWHc07AsKhlTG3UN0COb3Lxe9Keid5alsE2Qk794mYFRj4h0lb5EF8cWnU7BV_qSmPXsUyvbvYc2HkZIPtkuDFRo8Q08b-IhPd918jg5c_QI9HjYb5C_R_DpEdjuLtVsrvMuu2uJFiZc-vQOAJTaezyvsF2BxIsT3DQFB8Mv3Fg-r2XpzV82V_vUTw5BXemG3WE1VBSAST2fbpZ80SYI_nY_6JPn8Co0HZ9f9C9KcqEAMY2JN8pKB_5NT7iw3FrBBChqoEyMUdcaX4vLVdxRViilJmXLGOs6tzrXNE3A8svQ1OqoXtXuDMNW0jG1Mc0U1g1lKli71WBBaSLlNaIS-tONaLHeFM4rgcEhe7BhSAEOKwJDiLkI9P_T3X_qi1-HBYjUtGtYX1JXUSJdayTmzQklAX67MwKPUKo3zMkLHLeOKRhNvC5-7y2HWSpIIfbh_DTrkN0ZU7RYb-IZ55AodiSMk9hi-16H9NyCcoRp3I4wR-tqKxp_G__3Db_-7oXfoCQ2inIFCHaOj9Wrj3gMwWusOOmTxOVAxEUDlAK4f9c4uR1dw16fMU97vhGUHoEMmgV71fnSCAgEd09PfF90VKw
link.rule.ids 230,314,727,780,784,864,885,2102,2221,12056,12765,21388,24318,27924,27925,31719,31720,33373,33374,33744,33745,40901,41119,41120,41523,41970,42188,42189,42592,43310,43600,43805,51576,52095,52233,52234,53791,53793,73745,74035,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegk4AXxKcoG2AkHkBgLXEcx3lCbNoo0FYT6qS9Wf5KibQ1XT-k9p_ij-Av4y5NO2USvMaJ7Pg-_Ls73x0h77zMVZw6y0RIIya4cAxMMLBaM5cEkTvLHSY4D4aydy6-X6QXjcNt3lyr3OrEWlH7yqGP_BBzMCVwXxx_nl4z7BqF0dWmhcZdsoeV09MO2Ts6GZ793HlZsINJnqhttoySh_MYTtiIodWEx3PGVq0TqS7c30Kbt-9K3gqY1ufQ6SPysAGQ9MuG4o_JnTB5Qu4NmhD5U3I1qu92B09tWBi6ya9a06qgU0zwAGhJHVJ6RtEFS-Ms6y8ZsAI68D0dlJeL5aq8MvbPbwqbXtrKr6kZmxJgJB1frqeoNllM3389O2bxh2fk_PRkdNxjTU8F5oTIFiwvBFhAOZfBS-cBHSQggzZ2meHBYTEurL9juDHCKC5McD5I6W1ufR6D6ZEmz0lnUk3CC0K55UXkI54bbgXoKVWEBNEgzJBIH_Mu-bjdVz3dlM7QtcmhpN5QQQMVdE0FveqSI9z63ZtY9rp-UM3GupEizUPBnQqJV1IKnxkF-CsUKdiU1iRRXnTJwZZwupHFub7hnC55uxsGKcLQiJmEagnvCMSusJCoS7IWwVsLao9Myl91Pe6MA65T8OWnLWvcTP7vH375_7W-Ifd7o0Ff978Nf-yTB7xm2BRk6IB0FrNleAVYaGFfNwz_F5FDBuc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLagkyZeEFcRGGAkHkBgNXEcJ3lCbKwMWKsKbdLeLN_SRdqS0qZS-6f4EfwyjlOnUybBa5zIjs_tO_a5IPTW8DyLEq0Is0lIGGWagAsGXmuqY8tyrah2Cc7jCT85Z98vkgsf_7T0YZWdTmwVtam1OyMfuhxMDtwXRcPCh0VMv4w-zX8R10HK3bT6dhp30R5YxZAO0N7h8WT6c3fi4rqZ5HHWZc5kfLiMwNqGxHlQzlSnZN2zTm0R_x7yvB03eevytLVJowfovgeT-POW-g_RHVs9Qvtjf13-GF2ftXHe1mBlG4m3uVYbXBd47pI9AGZi7ai-wO44FkdperoiwBbuMN_gcXnVrNbltVR_fmMgQKlqs8FyJkuAlHh2tZk7FUoi_O7r9IhE75-g89Hx2dEJ8f0ViGYsbUheMPCGcsqt4doAUohBHlWkU0mtdoW5XC0eSaVkMqNMWm0s50blyuQRuCFJ_BQNqrqyzxCmihahCWkuqWKgs7LCxg4ZwgwxNxEN0IduX8V8W0ZDtO5HxsWWCgKoIFoqiHWADt3W7950JbDbB_ViJrxECWoLqjMbm4xzZlKZARazRQL-pZJxmBcBOugIJ7xcLsUNFwXozW4YJMpdk8jK1it4hzkcCwsJA5T2CN5bUH-kKi_b2twpBYyXwZcfO9a4mfzfP_z8_2t9jfaB18Xpt8mPF-gebfk1AXE6QINmsbIvARY16pXn97_djwsU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+beta+therapy+of+prostate+cancer+with+177Lu-labelled+Miltuximab%C2%AE+antibody+against+glypican-1+%28GPC-1%29&rft.jtitle=EJNMMI+research&rft.au=Yeh%2C+Mei-Chun&rft.au=Tse%2C+Brian+W.+C.&rft.au=Fletcher%2C+Nicholas+L.&rft.au=Houston%2C+Zachary+H.&rft.date=2020-05-07&rft.issn=2191-219X&rft.eissn=2191-219X&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13550-020-00637-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13550_020_00637_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2191-219X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2191-219X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2191-219X&client=summon